奥沙利铂联合替吉奥治疗晚期胆道肿瘤的临床效果分析被引量：1

导出

摘要目的对奥沙利铂联合替吉奥治疗晚期胆道肿瘤的临床效果进行观察。方法选取自2014年6月至2015年8月在我院接受治疗的100例晚期胆道肿瘤患者,给予奥沙利铂联合替吉奥治疗,每3周为1个周期,治疗2个周期后对临床治疗效果进行评价。结果 100例晚期胆道肿瘤患者均接受6个周期的化疗治疗,其中3例完全缓解,41例部分缓解,43例稳定,13例进展,总控制率为87%。不良反应主要有骨髓抑制、外周神经毒性与胃肠道反应。结论奥沙利铂联合替吉奥治疗晚期胆道肿瘤能够取得非常理想的治疗效果,不良反应能耐受,在临床中值得进一步推广应用。

作者雷海龙

机构地区内蒙古乌海市人民医院肿瘤科

出处《中国医药指南》 2016年第29期151-152,共2页 Guide of China Medicine

关键词奥沙利铂替吉奥晚期胆道肿瘤

分类号 R735.8 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1黄国军,王光红,高超,秦锴.替吉奥与卡培他滨联合奥沙利铂治疗晚期结直肠癌的临床研究[J].中国临床药理学杂志,2015,31(3):181-183. 被引量：32
2张春侠,章来长,王妍,赵胤铭,张晓元.奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者的临床疗效[J].现代生物医学进展,2014,14(31):6100-6102. 被引量：7
3牟海波,高扬,徐农.胆道肿瘤内科治疗进展[J].实用肿瘤杂志,2012,27(3):217-220. 被引量：6
4王红飞,薛建峰,许旭,夏晓波,赵龙栓.远端胆管癌的临床诊治进展[J].河南医学研究,2015,24(3):78-80. 被引量：1

二级参考文献48

1Vincenzo Cardinale,Rossella Semeraro,Alessia Torrice,Manuela Gatto,Cristina Napoli,Maria Consiglia Bragazzi,Raffaele Gentile,Domenico Alvaro.Intra-hepatic and extra-hepatic cholangiocarcinoma:New insight into epidemiology and risk factors[J].World Journal of Gastrointestinal Oncology,2010,2(11):407-416. 被引量：14
2Caitlin A Schonewolf,Monal Mehta,Devora Schiff,Hao Wu,Bruce G Haffty,Vassiliki Karantza,Salma K Jabbour.Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation[J].World Journal of Gastrointestinal Oncology,2014,6(3):74-82. 被引量：14
3Yukio Oshiro,Kazuhiro Takahashi,Ryoko Sasaki,Tadashi Kondo,Shingo Sakashita,Nobuhiro Ohkohchi.Adjuvant surgery for advanced extrahepatic cholangiocarcinoma[J].World Journal of Gastroenterology,2013,19(40):6934-6938. 被引量：1
4Takehiro Okabayashi,Yasuo Shima,Tatsuaki Sumiyoshi,Akihito Kozuki,Satoshi Ito,Yasuhiro Ogawa,Michiya Kobayashi,Kazuhiro Hanazaki.Diagnosis and management of insulinoma[J].World Journal of Gastroenterology,2013,19(6):829-837. 被引量：95
5Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study [J]. Lancet Oncol,2010,11 (12) :1142 - 1148.
6Malka D, Trarbach T, Fartoux Let al. A multicenter, randomized phase Ⅱ trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer : interim analysis of the BINGO trial [ J ]. J Clin Oncol, 2009,27 (15S): Abstr 4520.
7Andrew XZ, Meyerhardt JA, Lawrence S, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome :a phase Ⅱ study [J]. Lancet Oncol, 2010,11 ( 1 ) :48 - 54.
8Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase Ⅱ trial [J]. Br J Cancer, 2010,102( 1 ) :68 -72.
9Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a muhicenter phase Ⅱ trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase Ⅱ Consortium study [J]. J Clin Oncol, 2010, 28(21):3491-3497.
10Jensen LH, Jakobsen A. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma [J]. Expert Rev Anticancer Ther, 2011,11 (4) :589 - 600.